Age-related Normative Values for the Octopus 900 Perimeter (Norm-Oct900)

December 10, 2013 updated by: Ulrich Schiefer, University Hospital Tuebingen

Normal Values for the Full Visual Field, Corrected for Age- and Reaction Time, Using Semi-automated Kinetic Testing on the Octopus 900 Perimeter

The purpose of this study is to determine normal values of the visual field (VF), corrected for age- and reaction time (RT) using the Octopus 900 perimeter and semi-automated kinetic perimetry (SKP).

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Baden-Württemberg
      • Tübingen, Baden-Württemberg, Germany, 72076
        • Centre for Ophthalmology / Institute for Ophthalmic Research, University of Tübingen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years to 79 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • maximum spherical ametropia ± 6 Diopters (D)
  • maximum cylindrical ametropia ± 2 D
  • distant visual acuity ≥ 1.0 logMAR [20/20] for subjects up to 60 years, ≥ 0.8 logMAR [20/25] for subjects from 61-70 years, ≥ 0.63 logMAR [20/30] for subjects older than 70 years
  • isocoria, pupil diameter > 3mm
  • intraocular pressure (air pulse tonometer) ≤ 21mmHg
  • normal anterior segments
  • ocular fundus: normal appearance of the cup to disc ratio (CDR) ≤ 0.5, interocular difference of CDR < 0.3
  • normal macular region, vessels, and peripheral retinal examination (with undilated pupils).

Exclusion Criteria:

  • amblyopia
  • strabismus
  • ocular motility disorder
  • diseases of the retina
  • glaucoma, glaucoma suspect
  • macular degeneration
  • IOP > 21 mmHg
  • abnormal color vision test (ISPP - Ishihara and Standard Pseudoisochromatic Plates = SPP)
  • history or findings of other neuro-ophthalmological disease
  • relevant opacities of the central refractive media (cornea, lens, vitreous body)
  • use of miotic drugs
  • intraocular surgery (except uncomplicated cataract surgery, more than three months previous to testing)
  • kerato-refractive surgery (LASIK)
  • drugs influencing reaction time
  • drugs indicating severe general diseases (anti-diabetic pharmaceuticals and anti-hypertensive medication were allowed for subjects older than 70 years)
  • mental diseases (for example psychosis)
  • pregnancy, nursing
  • acute infections
  • heavy smoking (>10 cigarettes /day)
  • alcohol abuse
  • diabetic retinopathy
  • coronary heart disease
  • stroke
  • migraine
  • Raynaud's syndrome
  • suspected lack of compliance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: one arm
observational study, no cohort, single group of different ages

We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .

The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement of the full Visual Field using semi-automated kinetic perimetry.
Time Frame: one day
additional a subgroup of 14 participants were tested at 3 separate sessions within 4 weeks.
one day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Ulrich Schiefer, Prof. Dr. med., Centre for Ophthalmology / Institute for Ophthalmic Research, University of Tübingen, Germany

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2006

Primary Completion (Actual)

March 1, 2008

Study Completion (Actual)

September 1, 2008

Study Registration Dates

First Submitted

January 12, 2012

First Submitted That Met QC Criteria

January 25, 2012

First Posted (Estimate)

January 26, 2012

Study Record Updates

Last Update Posted (Estimate)

December 11, 2013

Last Update Submitted That Met QC Criteria

December 10, 2013

Last Verified

December 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)

3
Subscribe